About Krabbe Disease Treatment
Krabbe disease is a rare inherited genetic disorder that affects the nervous system. It is usually caused by the deficiency of the galactosylceramidase (GLC) enzyme. The disease is inherited in an autosomal recessive pattern.
Technavio’s analysts forecast the global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global krabbe disease treatment market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Krabbe Disease Treatment Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
Market driver
• Special drug designation
• For a full, detailed list, view our report
Market challenge
• Limited patient pool for clinical trials
• For a full, detailed list, view our report
Market trend
• Emergence of pharmacological chaperone therapy
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
• Types of Krabbe disease
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE ANALYSIS
PART 09: MARKET SEGMENTATION BY THERAPY
• Segmentation by therapy
• Comparison by therapy
• Global Krabbe disease treatment market by anticonvulsants
• Global Krabbe disease treatment market by muscle relaxants
• Global Krabbe disease treatment market by HSCT
• Global Krabbe disease treatment market by others
• Market opportunity by therapy
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Krabbe disease treatment market in Americas
• Krabbe disease treatment market in EMEA
• Krabbe disease treatment market in APAC
• Key leading countries
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Emergence of pharmacological chaperone therapy
• Gene technology in therapy
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
PART 17: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Types of Krabbe disease
Exhibit 02: Parent market
Exhibit 03: Global rare diseases treatment market: Segmentation
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition: Inclusions and exclusions checklist
Exhibit 07: Market size
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global Krabbe disease treatment market 2017-2022 ($ millions)
Exhibit 10: Global Krabbe disease treatment market: Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global Krabbe disease treatment market
Exhibit 20: Global Krabbe disease treatment market by therapy 2017-2022 (% share)
Exhibit 21: Comparison by therapy
Exhibit 22: Global Krabbe disease treatment market by anticonvulsants 2017-2022 ($ millions)
Exhibit 23: Global Krabbe disease treatment market by anticonvulsants: Year over year growth 2018-2022 (%)
Exhibit 24: Global Krabbe disease treatment market by muscle relaxants 2017-2022 ($ millions)
Exhibit 25: Global Krabbe disease treatment market by muscle relaxants: Year over year growth 2018-2022 (%)
Exhibit 26: Global Krabbe disease treatment market by HSCT 2017-2022 ($ millions)
Exhibit 27: Global Krabbe disease treatment market by HSCT: Year over year growth 2018-2022 (%)
Exhibit 28: Global Krabbe disease treatment market by others 2017-2022 ($ millions)
Exhibit 29: Global Krabbe disease treatment market by others: Year over year growth 2018-2022 (%)
Exhibit 30: Market opportunity by therapy
Exhibit 31: Customer landscape
Exhibit 32: Global Krabbe disease treatment market by region 2017-2022 (% share)
Exhibit 33: Regional comparison
Exhibit 34: Krabbe disease treatment market in Americas 2017-2022 ($ millions)
Exhibit 35: Krabbe disease treatment market in Americas: Year over year growth 2018-2022 (%)
Exhibit 36: Krabbe disease treatment market in EMEA 2017-2022 ($ millions)
Exhibit 37: Krabbe disease treatment market in EMEA: Year over year growth 2018-2022 (%)
Exhibit 38: Krabbe disease treatment market in APAC 2017-2022 ($ millions)
Exhibit 39: Krabbe disease treatment market in APAC: Year over year growth 2018-2022 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Some long-term complications in HSCT patients
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: GlaxoSmithKline: Overview
Exhibit 49: GlaxoSmithKline: Business segments
Exhibit 50: GlaxoSmithKline: Organizational developments
Exhibit 51: GlaxoSmithKline: Geographic focus
Exhibit 52: Johnson & Johnson: Segment focus
Exhibit 53: GlaxoSmithKline: Key offerings
Exhibit 54: GlaxoSmithKline: Key customers
Exhibit 55: Johnson & Johnson: Overview
Exhibit 56: Johnson & Johnson: Business segments
Exhibit 57: Johnson & Johnson: Organizational developments
Exhibit 58: Johnson & Johnson: Geographic focus
Exhibit 59: Johnson & Johnson: Segment focus
Exhibit 60: Johnson & Johnson: Key offerings
Exhibit 61: Johnson & Johnson: Key customers
Exhibit 62: Novartis: Overview
Exhibit 63: Novartis: Business segments
Exhibit 64: Novartis: Organizational developments
Exhibit 65: Novartis: Geographic focus
Exhibit 66: Novartis: Segment focus
Exhibit 67: Novartis: Key offerings
Exhibit 68: Novartis: Key customers
